Upstream Bio Company Insiders

Upstream Bio Management Team Effectiveness

The company has Return on Asset of (0.2815) % which means that on every $100 spent on assets, it lost $0.2815. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.408) %, meaning that it generated no profit with money invested by stockholders. Upstream Bio's management efficiency ratios could be used to measure how well Upstream Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.12. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, Upstream Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.1 M, whereas Other Current Assets are forecasted to decline to about 5.6 M. As of February 2, 2026, Common Stock Shares Outstanding is expected to decline to about 45.5 MUpstream Bio shows a total of 54.04 Million outstanding shares. The majority of Upstream Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Upstream Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Upstream Bio. Please pay attention to any change in the institutional holdings of Upstream Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly four million three hundred sixty thousand nine hundred fourteen invesors are currently shorting Upstream Bio expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as Upstream Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Upstream Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Upstream Bio Workforce Comparison

Upstream Bio Insider Trading

Upstream Bio Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Upstream Bio often depends on how effective the management is. Upstream Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Upstream management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Upstream management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Upstream Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Upstream Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Upstream Bio's management manipulating its earnings.

When running Upstream Bio's price analysis, check to measure Upstream Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio is operating at the current time. Most of Upstream Bio's value examination focuses on studying past and present price action to predict the probability of Upstream Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio's price. Additionally, you may evaluate how the addition of Upstream Bio to your portfolios can decrease your overall portfolio volatility.